BT04

BT04 is a preclinical-stage drug candidate being developed by BioTroy Therapeutics, a Shanghai-based biopharmaceutical company. BioTroy Therapeutics focuses on the discovery and development of first-in-class cancer immunotherapies, particularly monoclonal antibodies targeting solid tumors. While the company's other pipeline assets (BT01 and BT02) are identified as monoclonal antibodies for specific solid tumors like gastric and lung cancer, the specific indication, molecular target, and mechanism of action for BT04 remain undisclosed. It is currently positioned in the early stages of development for the treatment of neoplasms.